Acta ophthalmologica · 2010
Retinal vascular events after intravitreal bevacizumab.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mansour Ahmad M, Bynoe Leon A, Welch John C, Pesavento Richard, Mahendradas Padmamalini, Ziemssen Focke, Pai Sivakami A
Аннотация
PURPOSE: To record retinal vascular events following intravitreal bevacizumab injection.
METHODS: Collaborative multi-centre retrospective case series.
RESULTS: Eight patients were documented to have central retinal artery occlusion (four patients), branch retinal artery occlusion, capillary occlusion, central retinal vein occlusion and branch retinal vein occlusion (one patient each) within 0-55 days (median 2 weeks) of intravitreal bevacizumab. All patients had several ocular and systemic risk factors for retinal vascular events: elevated intraocular pressure on discharge (four patients), pre-existent glaucoma (one patient), pre-existent ischaemic retinal vascular disorder (four patients), systemic hypertension (five patients), diabetes mellitus (three patients), coronary artery disease (four patients), carotid disease (three patients), smoking (two patients) and migraine (one patient).
CONCLUSION: The retinal vascular events may be associated with the underlying ocular disease under treatment or with the underlying systemic disease, may be related to an increased intraocular pressure post-injection constraining further an already poor retinal perfusion, the vasoconstrictor effect of bevacizumab, or a combination of all three.
METHODS: Collaborative multi-centre retrospective case series.
RESULTS: Eight patients were documented to have central retinal artery occlusion (four patients), branch retinal artery occlusion, capillary occlusion, central retinal vein occlusion and branch retinal vein occlusion (one patient each) within 0-55 days (median 2 weeks) of intravitreal bevacizumab. All patients had several ocular and systemic risk factors for retinal vascular events: elevated intraocular pressure on discharge (four patients), pre-existent glaucoma (one patient), pre-existent ischaemic retinal vascular disorder (four patients), systemic hypertension (five patients), diabetes mellitus (three patients), coronary artery disease (four patients), carotid disease (three patients), smoking (two patients) and migraine (one patient).
CONCLUSION: The retinal vascular events may be associated with the underlying ocular disease under treatment or with the underlying systemic disease, may be related to an increased intraocular pressure post-injection constraining further an already poor retinal perfusion, the vasoconstrictor effect of bevacizumab, or a combination of all three.
Предметные рубрики MeSH
AdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBevacizumabCoronary Artery DiseaseDiabetic RetinopathyEye DiseasesFemaleFluorescein AngiographyFundus OculiGlaucomaHumansHypertensionInjections, IntraocularMaleMiddle AgedOcular HypertensionRetinal Artery OcclusionRetinal DiseasesRetinal Vein OcclusionRetrospective StudiesRisk FactorsSmokingVasoconstrictor AgentsVitreous Body